Please ensure Javascript is enabled for purposes of website accessibility

Here's Why NantKwest Rocketed Higher Today

By Brian Orelli, PhD – Jun 22, 2020 at 2:03PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Investors are excited about the biotech's COVID-19 vaccine targeting a different part of the novel coronavirus.

What happened

Shares of NantKwest (NK) are up 40% at 12:40 p.m. EDT after the company's CEO Patrick Soon-Shiong made an appearance on Fox Business' Maria Bartiromo's Wall Street to talk about NantKwest's COVID-19 vaccine.

So what

While other companies such as Moderna (MRNA -0.55%) and Inovio (INO -3.39%) are developing vaccines to create antibodies to the spike protein on the outside of the virus, which should block the virus from entering the patient's cell, NantKwest has developed a vaccine expressing both the spike protein and the nucleocapsid protein on the inside of the virus.

Soon-Shiong hypothesizes that the nucleocapsid protein will be required to create memory T-cells that provide long-term immunity because patients who have survived other coronavirus outbreaks only had long-term memory T-cells that target the nucleocapsid protein.

Gloved hands about to give an injection into a shoulder

Image source: Getty Images.

The biotech has applied to the Biomedical Advanced Research and Development Authority (BARDA) for funding to ramp up production of the vaccine, but is still in talks with the government agency. NantKwest's vaccine, which is ready to start clinical trials, wasn't included in the five vaccines for Operation Warp Speed.

Now what

NantKwest is most famous for the cancer treatments that it's developing, and investors should continue to focus on its pipeline of drugs treating a wide range of tumor types. The drugs are still in early-stage development, and an infusion of cash from a successful COVID-19 vaccine would certainly help. But ultimately, NantKwest is going to live and die by its cancer platform, so investors shouldn't get distracted by the one-time benefit of a COVID-19 vaccine.

Brian Orelli and The Motley Fool have no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

NantKwest, Inc. Stock Quote
NantKwest, Inc.
NK
Inovio Pharmaceuticals, Inc. Stock Quote
Inovio Pharmaceuticals, Inc.
INO
$1.71 (-3.39%) $0.06
Moderna, Inc. Stock Quote
Moderna, Inc.
MRNA
$123.64 (-0.55%) $0.68

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
329%
 
S&P 500 Returns
106%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 09/25/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.